FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197156785> ?p ?o ?g. }

• W3197156785 endingPage "S62" @default.
• W3197156785 startingPage "S61" @default.
• W3197156785 abstract "Introduction Marginal zone lymphomas (MZL) are indolent diseases with a heterogeneous presentation. Extranodal MZL of the mucosa-associated lymphoid tissue is the most common type, accounting for nearly 70% of all MZL, with the possible involvement of any anatomic site. Splenic MZL represents roughly 20% of cases, while nodal MZL is the most infrequent entity. Overall survival rates are very good, but disease relapse is frequent and can occur several times, with possible impairment of patients’ quality of life. For this reason, multiple lines of treatment may be required, generally starting with an approach that allows for effective local control of the disease, with no (or just a few) harmful side effects. Initial approaches mainly consist of radiation therapy, surgical excision, or administration of monoclonal antibodies. Systemic treatments and chemotherapy are conceived as an option in multiple-relapsing disease, in case of advanced stage at presentation or relapse, or if initial local treatments lack efficacy.1 Targeted agents and new drugs can provide chemo-free alternatives in heavily pretreated patients. The newest drugs currently applied in patients with relapsed or refractory MZL, as well as agents under development, are briefly reviewed here. Marginal zone lymphomas (MZL) are indolent diseases with a heterogeneous presentation. Extranodal MZL of the mucosa-associated lymphoid tissue is the most common type, accounting for nearly 70% of all MZL, with the possible involvement of any anatomic site. Splenic MZL represents roughly 20% of cases, while nodal MZL is the most infrequent entity. Overall survival rates are very good, but disease relapse is frequent and can occur several times, with possible impairment of patients’ quality of life. For this reason, multiple lines of treatment may be required, generally starting with an approach that allows for effective local control of the disease, with no (or just a few) harmful side effects. Initial approaches mainly consist of radiation therapy, surgical excision, or administration of monoclonal antibodies. Systemic treatments and chemotherapy are conceived as an option in multiple-relapsing disease, in case of advanced stage at presentation or relapse, or if initial local treatments lack efficacy.1 Targeted agents and new drugs can provide chemo-free alternatives in heavily pretreated patients. The newest drugs currently applied in patients with relapsed or refractory MZL, as well as agents under development, are briefly reviewed here." @default.
• W3197156785 created "2021-09-13" @default.
• W3197156785 creator A5090561717 @default.
• W3197156785 creator A5091882595 @default.
• W3197156785 date "2021-09-01" @default.
• W3197156785 modified "2023-10-16" @default.
• W3197156785 title "New Agents in Marginal Zone Lymphomas" @default.
• W3197156785 cites W3107020624 @default.
• W3197156785 cites W3107315341 @default.
• W3197156785 cites W3126964460 @default.
• W3197156785 cites W3135092227 @default.
• W3197156785 cites W3156264646 @default.
• W3197156785 doi "https://doi.org/10.1016/s2152-2650(21)01211-8" @default.
• W3197156785 hasPublicationYear "2021" @default.
• W3197156785 type Work @default.
• W3197156785 sameAs 3197156785 @default.
• W3197156785 citedByCount "0" @default.
• W3197156785 crossrefType "journal-article" @default.
• W3197156785 hasAuthorship W3197156785A5090561717 @default.
• W3197156785 hasAuthorship W3197156785A5091882595 @default.
• W3197156785 hasConcept C142724271 @default.
• W3197156785 hasConcept C159654299 @default.
• W3197156785 hasConcept C203014093 @default.
• W3197156785 hasConcept C2778453870 @default.
• W3197156785 hasConcept C2778563104 @default.
• W3197156785 hasConcept C2779338263 @default.
• W3197156785 hasConcept C2779921676 @default.
• W3197156785 hasConcept C71924100 @default.
• W3197156785 hasConceptScore W3197156785C142724271 @default.
• W3197156785 hasConceptScore W3197156785C159654299 @default.
• W3197156785 hasConceptScore W3197156785C203014093 @default.
• W3197156785 hasConceptScore W3197156785C2778453870 @default.
• W3197156785 hasConceptScore W3197156785C2778563104 @default.
• W3197156785 hasConceptScore W3197156785C2779338263 @default.
• W3197156785 hasConceptScore W3197156785C2779921676 @default.
• W3197156785 hasConceptScore W3197156785C71924100 @default.
• W3197156785 hasLocation W31971567851 @default.
• W3197156785 hasOpenAccess W3197156785 @default.
• W3197156785 hasPrimaryLocation W31971567851 @default.
• W3197156785 hasRelatedWork W1995162296 @default.
• W3197156785 hasRelatedWork W2045290973 @default.
• W3197156785 hasRelatedWork W2046728107 @default.
• W3197156785 hasRelatedWork W2049841019 @default.
• W3197156785 hasRelatedWork W2059977198 @default.
• W3197156785 hasRelatedWork W2079738342 @default.
• W3197156785 hasRelatedWork W2084050779 @default.
• W3197156785 hasRelatedWork W2116815461 @default.
• W3197156785 hasRelatedWork W2590056737 @default.
• W3197156785 hasRelatedWork W3184484902 @default.
• W3197156785 hasVolume "21" @default.
• W3197156785 isParatext "false" @default.
• W3197156785 isRetracted "false" @default.
• W3197156785 magId "3197156785" @default.
• W3197156785 workType "article" @default.